Table 1 Medical history and histopathological data of study participants.
From: Influence of the duration of type 2 diabetes mellitus on colorectal cancer outcomes
Clinicopathological characteristics | Without T2DM (n = 613) | With T2DM (n = 204) | P value |
|---|---|---|---|
Age (year) | 64.42 ± 11.61 | 67.85 ± 8.27 | < 0.001 |
Male:female ratio | 317:296 (51.7%:48.3%) | 139:65 (68.1%:31.9%) | < 0.001 |
Irresectable tumor | 50 (8.2%) | 17 (8.3%) | 1.000 |
AJCC staging45 at tumor diagnosis: | 0.882 | ||
Stage I | 67 (10.9%) | (17.2%) | |
Stage II | 159 (25.9%) | 24.5%) | |
Stage III | 134 (21.9%) | 48 (23.5%) | |
Stage IV | 253 (41.3%) | 71 (34.8%) | |
Regional lymph node metastasis | 279 (45.5%) | 92 (45.1%) | 1.000 |
Distant metastases: | 1.000 | ||
Synchronous | 253 (41.3%) | 71 (34.8%) | |
Metachronous | 75 (12.2%) | 22 (10.8%) | |
Location of the tumor46: | 1.000 | ||
Left-sided | 416 (67.9%) | 0.1%) | |
Right-sided | 183 (29.9%) | 56 (27.5%) | |
Both (multiplex tumor) | 14 (2.3%) | 5 (2.5%) | |
Neoadjuvant chemotherapy | 68 (11.1%) | 18 (8.8%) | 1.000 |
Final lineage of chemotherapy | 1.000 | ||
Adjuvant only/First line | 281 (45.8%) | 42.6%) | |
Second line | 71 (11.6%) | 25 (12.3%) | |
Third line or above | 81 (13.2%) | 21 (10.3%) | |
Radiotherapy | 1.000 | ||
Preoperative | 46 (7.5%) | 7.8%) | |
Postoperative | 49 (8.0%) | 14 (6.8%) | |
Pre- and postoperative | 4 (0.7%) | 1 (0.5%) | |
Use of biological agentsa | 182 (29.7%) | 42 (20.6%) | 0.147 |
Use of regorafenib or trifluridine/tipiracil | 43 (7.0%) | 10 (4.9%) | 1.000 |
Medical history | |||
Hypertension | 370 (60.4%) | 184 (90.2%) | < 0.001 |
Major cardiovascular event(s)b prior to CRC | 88 (14.4%) | 63 (30.9%) | < 0.001 |
Thyroid disease (in euthyroid state) | 57 (9.3%) | 25 (12.3%) | 1.000 |
Appendectomy | 93 (15.2%) | 47 (23.0%) | 0.160 |
Cholecystectomy | 82 (13.4%) | 39 (19.1%) | 0.581 |
Medications | |||
Antihypertensive therapy | 345 (56.3%) | 174 (85.3%) | < 0.001 |
Statin therapy | 86 (14.0%) | 63 (30.9%) | < 0.001 |
Aggregation inhibition | 85 (13.9%) | 68 (33.3%) | < 0.001 |
